Update on XBP1 in liver pathobiology
Seminars in Liver Disease · 11.11.2026
DOI: 10.1055/a-2998-1982 ↗Kurz gefasst
Fachartikel in der Zeitschrift Seminars in Liver Disease, erschienen am 11.11.2026. Verfasst von Ryan Philip Henry Shaw und 1 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern University Feinberg School of Medicine, Comprehensive Transplant Center, Illinois, United States, Chicago. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Max Goldenberg Fund, Division of Diabetes, Endocrinology, and Metabolic Diseases, Scott Family Fund for Cholestatic Liver Disease.
Abstract (Originalsprache)
Chronic liver disease is a major cause of global morbidity and mortality, yet disease-modifying therapies remain scarce. A shared mechanism uniting metabolic, alcohol-associated, viral, drug-induced, cholestatic, and genetic liver injury is endoplasmic reticulum stress and activation of the unfolded protein response. The transcription factor X-box binding protein 1-spliced, a principal output of the inositol-requiring enzyme 1α arm of this response, has emerged as a central determinant of disease pathogenesis. Under endoplasmic reticulum stress, inositol-requiring enzyme 1α splices X-box binding protein 1 messenger RNA to generate the spliced protein, which increases protein folding and degradation capacity and governs hepatic lipogenesis and lipoprotein assembly. A defining feature, however, is its functional dichotomy: typically cytoprotective in hepatocytes but pathogenic in macrophages and stellate cells, and adaptive during transient but maladaptive during unresolved or excessive stress. This dichotomy sans the spectrum of liver diseases and explains, in part, why global manipulation of the pathway has yielded conflicting results and has obstructed targeted drug development. In conclusion, cell-type selectivity is the central translational challenge, preserving protective hepatocyte signaling while restraining it in non-parenchymal cells, which may be addressed through targeted delivery of pharmacologic or genetic therapeutics directed at this pathway in animal models and humans.
Autor:innen und Institutionen
- Northwestern University Feinberg School of Medicine, Comprehensive Transplant Center, Illinois, United States, Chicago.
- Northwestern University Feinberg School of Medicine, Professor of Medicine, Gastroenterology and Hepatology, Illinois, United States, Chicago.
ORCID-Profile: Ryan Philip Henry Shaw, Richard M Green
Förderung
- Max Goldenberg Fund
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- Scott Family Fund for Cholestatic Liver Disease
- Northwestern Medicine
Zitieren
APA
Shaw, R. P. H., & Green, R. M. (2026). Update on XBP1 in liver pathobiology. Seminars in Liver Disease. https://doi.org/10.1055/a-2998-1982
Vancouver
Shaw RPH, Green RM. Update on XBP1 in liver pathobiology. Seminars in Liver Disease. 2026. doi:10.1055/a-2998-1982
BibTeX
@article{Shaw2026,
author = {Shaw, Ryan Philip Henry and Green, Richard M},
title = {Update on XBP1 in liver pathobiology},
journal = {Seminars in Liver Disease},
year = {2026},
doi = {10.1055/a-2998-1982}
}
EUVIMED